{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:42Z","timestamp":1791876942584,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T00:00:00Z","timestamp":1679443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>IDH1 and IDH2 are among the most commonly mutated genes in myeloid neoplasms (MNs). It has been proposed that IDH2 R172 mutations (mR172) define a molecular subtype of acute myeloid leukemia (AML), but the clinicopathologic features of AML with mR172 have not been fully described.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively identified and characterized all mR172 MNs with increased blasts in our archive for comparison to a similar number of MNs with IDH2 R140 (mR140) and IDH1 R132 (mR132) mutations (n = 39).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>mR172 cases had lower leukocyte counts and bone marrow cellularity than did non-mR172 cases. mR172 MNs often displayed blasts with highly invaginated, cleaved nuclei and typically expressed CD34, HLA-DR, CD117, and CD13 but often with diminished CD33. mR172 cases often had co-occurring mutations in myelodysplasia-associated genes and\/or an adverse karyotype. Despite frequent adverse-risk genetic changes, in our cohort mR172 cases had significantly improved overall survival vs non-mR172 cases (P = .01), and we validated that mR172 was associated with improved survival in an independent large data set.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>We show that MNs with mR172 represent a morphologically and phenotypically distinct subtype, which in our cohort exhibited relatively favorable survival that is not captured in current AML risk assignment.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad019","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T12:17:47Z","timestamp":1679487467000},"page":"89-97","source":"Crossref","is-referenced-by-count":1,"title":["Clinicopathologic Features of <i>IDH2<\/i> R172\u2013Mutated Myeloid Neoplasms"],"prefix":"10.1093","volume":"160","author":[{"given":"Adam R","family":"Davis","sequence":"first","affiliation":[{"name":"Department of Pathology, UPMC , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Briana C","family":"Canady","sequence":"additional","affiliation":[{"name":"University of Pittsburgh School of Medicine , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0277-0132","authenticated-orcid":false,"given":"Nidhi","family":"Aggarwal","sequence":"additional","affiliation":[{"name":"Department of Pathology, UPMC , Pittsburgh, PA , USA"},{"name":"University of Pittsburgh School of Medicine , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6747-680X","authenticated-orcid":false,"given":"Nathanael G","family":"Bailey","sequence":"additional","affiliation":[{"name":"Department of Pathology, UPMC , Pittsburgh, PA , USA"},{"name":"University of Pittsburgh School of Medicine , Pittsburgh, PA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,22]]},"reference":[{"key":"2023070513430347800_CIT0001","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"N Engl J Med."},{"key":"2023070513430347800_CIT0002","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N Engl J Med."},{"key":"2023070513430347800_CIT0003","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N Engl J Med."},{"key":"2023070513430347800_CIT0004","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme.","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"2023070513430347800_CIT0005","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med."},{"key":"2023070513430347800_CIT0006","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1200\/JCO.2010.28.2285","article-title":"Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group","volume":"28","author":"Boissel","year":"2010","journal-title":"J Clin Oncol."},{"key":"2023070513430347800_CIT0007","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell."},{"key":"2023070513430347800_CIT0008","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol."},{"key":"2023070513430347800_CIT0009","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/leu.2010.77","article-title":"IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia."},{"key":"2023070513430347800_CIT0010","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J Clin Oncol."},{"key":"2023070513430347800_CIT0011","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting \u03b1-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell."},{"key":"2023070513430347800_CIT0012","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","author":"Medeiros","year":"2017","journal-title":"Leukemia."},{"key":"2023070513430347800_CIT0013","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","article-title":"Biological role and therapeutic potential of IDH mutations in cancer","volume":"34","author":"Waitkus","year":"2018","journal-title":"Cancer Cell."},{"key":"2023070513430347800_CIT0014","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N Engl J Med."},{"key":"2023070513430347800_CIT0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1309\/AJCPD7NR2RMNQDVF","article-title":"Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features","volume":"135","author":"Patel","year":"2011","journal-title":"Am J Clin Pathol."},{"key":"2023070513430347800_CIT0016","doi-asserted-by":"crossref","first-page":"4622","DOI":"10.1038\/s41467-022-32103-8","article-title":"Unified classification and risk-stratification in acute myeloid leukemia","volume":"13","author":"Tazi","year":"2022","journal-title":"Nat Commun."},{"key":"2023070513430347800_CIT0017","article-title":"yanistazi\/Tazi\\_NatureC\\_AML: Nature Paper release","author":"Tazi","year":"2022"},{"key":"2023070513430347800_CIT0018","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 ELN recommendations from an International Expert Panel","author":"D\u00f6hner","year":"2022","journal-title":"Blood."},{"key":"2023070513430347800_CIT0019","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","author":"Arber","year":"2022","journal-title":"Blood."},{"key":"2023070513430347800_CIT0020","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia."},{"key":"2023070513430347800_CIT0021","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1182\/blood-2010-12-322479","article-title":"The prognostic significance of IDH2 mutations in AML depends on the location of the mutation","volume":"118","author":"Green","year":"2011","journal-title":"Blood."},{"key":"2023070513430347800_CIT0022","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41375-018-0026-z","article-title":"IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies","volume":"32","author":"Meggendorfer","year":"2018","journal-title":"Leukemia."},{"key":"2023070513430347800_CIT0023","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2021004934","article-title":"Differential impact of IDH1\/2 mutational subclasses on outcome in adult AML: results from a large multicenter study","volume":"6","author":"Middeke","year":"2022","journal-title":"Blood Adv."},{"key":"2023070513430347800_CIT0024","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/blood.V126.23.320.320","article-title":"Significance of blast CD33 expression for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukemia: results from the UK NCRI AML16\/17 trials","volume":"126","author":"Naeem","year":"2015","journal-title":"Blood."},{"key":"2023070513430347800_CIT0025","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1182\/blood-2016-01-689976","article-title":"The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia","volume":"127","author":"Olombel","year":"2016","journal-title":"Blood."},{"key":"2023070513430347800_CIT0026","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med."},{"key":"2023070513430347800_CIT0027","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/ajh.25018","article-title":"A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1\/2 mutations and improved outcome.","volume":"93","author":"Mason","year":"2018","journal-title":"Am J Hematol."},{"key":"2023070513430347800_CIT0028","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1182\/blood-2010-11-320937","article-title":"Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia","volume":"117","author":"Boissel","year":"2011","journal-title":"Blood."},{"key":"2023070513430347800_CIT0029","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/2050-7771-2-18","article-title":"Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C &gt; T have a prognostic value in acute myeloid leukemia","volume":"2","author":"Willander","year":"2014","journal-title":"Biomark Res."},{"key":"2023070513430347800_CIT0030","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1182\/blood.2020010165","article-title":"Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study","volume":"137","author":"Duchmann","year":"2021","journal-title":"Blood."},{"key":"2023070513430347800_CIT0031","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3389\/fonc.2019.00417","article-title":"Mutant isocitrate dehydrogenase inhibitors as targeted cancer therapeutics","volume":"9","author":"Golub","year":"2019","journal-title":"Front Oncol."},{"key":"2023070513430347800_CIT0032","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1182\/blood-2017-04-779447","article-title":"Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response","volume":"130","author":"Amatangelo","year":"2017","journal-title":"Blood."},{"key":"2023070513430347800_CIT0033","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood."},{"key":"2023070513430347800_CIT0034","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood."},{"key":"2023070513430347800_CIT0035","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med."},{"key":"2023070513430347800_CIT0036","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/s41591-020-1089-8","article-title":"Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial","volume":"26","author":"Burd","year":"2020","journal-title":"Nat Med."},{"key":"2023070513430347800_CIT0037","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-021-00497-1","article-title":"Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm","volume":"11","author":"Issa","year":"2021","journal-title":"Blood Cancer J."},{"key":"2023070513430347800_CIT0038","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/1\/89\/50822331\/aqad019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/1\/89\/50822331\/aqad019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,5]],"date-time":"2023-07-05T19:16:57Z","timestamp":1688584617000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/160\/1\/89\/7083610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,22]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,22]]},"published-print":{"date-parts":[[2023,7,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad019","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,1]]},"published":{"date-parts":[[2023,3,22]]}}}